27851-28-1

Basic information

• Product Name: 6-O-Trityl-1,2,3,4-tetra-O-benzyl-β-D-glucopyranose
• Synonyms: 6-O-Trityl-1,2,3,4-tetra-O-benzyl-β-D-glucopyranose;1,2,3,4-Tetra-O-benzyl-6-O-trityl-beta-D-glucopyranose;1,2,3,4-Tetra-O-benzyl-6-O-trityl-b-D-glucopyranose;Benzyl 2,3,4-tri-O-benzyl-6-O-trityl-beta-D-glucopyranoside;Phenylmethyl 2,3,4-tris-O-(phenylmethyl)-6-O-(triphenylmethyl)-beta-D-glucopyranoside
• CAS NO: 27851-28-1
• Molecular Formula: C₅₃H₅₀O₆
• Molecular Weight: 782.96
• Product Categories: Carbohydrates
• Mol File: 27851-28-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-O-Trityl-1,2,3,4-tetra-O-benzyl-β-D-glucopyranose(CAS DataBase Reference)
• NIST Chemistry Reference: 6-O-Trityl-1,2,3,4-tetra-O-benzyl-β-D-glucopyranose(27851-28-1)
• EPA Substance Registry System: 6-O-Trityl-1,2,3,4-tetra-O-benzyl-β-D-glucopyranose(27851-28-1)

Safety Data

• Hazardous Substances Data: 27851-28-1(Hazardous Substances Data)

Upstream product

• 39687-20-2 (2R,3R,4S,5S,6R)-2-(benzyloxy)-6-((trityloxy)methyl)tetrahydro-2H-pyran-3,4,5-triol 
• 100-39-0 benzyl bromide 
• 54325-28-9 6-O-trityl-D-glucopyranose 
• 2280-44-6 D-Glucose 
• 76-83-5 trityl chloride 
• 4304-12-5 (2R,3R,4S,5S,6R)-2-(benzyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 10343-13-2 benzyl-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 
• 1235200-84-6 (3R)-3-(6-O-trityl-β-D-glucopyranosyloxy)-4-pentenoic acid tert-butyl ester 
• 66966-07-2 α/β‐L‐glucopyranosyl‐1,2,3,4,5‐pentaacetate 
• 100-51-6 benzyl alcohol 

Downstream Products

• 27851-29-2 benzyl 2,3,4-tri-O-benzyl-D-glucopyranoside 
• 566905-62-2 benzyl 2,3,4-tri-O-benzyl-6-O-imidazol-N-ylcarbonyl-β-D-glucopyranoside 
• 566905-73-5 benzyl 2,3,4-tri-O-benzyl-β-D-glucopyranoside 6-(hydrogen succinate) 
• 566905-64-4 benzyl 2,3,4-tri-O-benzyl-6-O-[N-(3,4-dibenzyloxyphenylethyl)aminocarbonyl]-β-D-glucopyranoside 
• 331233-69-3 (4aS,6R,7R,8R,8aR)-8-Benzyloxy-2,2-dimethyl-6-((2R,3R,4S,5R,6R)-3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ol 
• 404378-60-5 (2S,3R,4S,5R,6R)-4-Benzyloxy-2-hydroxymethyl-6-((2R,3R,4S,5R,6R)-3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-tetrahydro-pyran-3,5-diol 
• 331233-71-7 (2R,3S,4S,5R,6R)-5-Acetoxy-4-benzyloxy-3-hydroxy-6-((2R,3R,4S,5R,6R)-3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 331233-70-6 Acetic acid (2R,3R,4S,5R,6S)-4-benzyloxy-5-hydroxy-6-hydroxymethyl-2-((2R,3R,4S,5R,6R)-3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-tetrahydro-pyran-3-yl ester 
• 331233-68-2 Acetic acid (2R,3R,4S,5R,6S)-5-acetoxy-6-acetoxymethyl-4-benzyloxy-2-((2R,3R,4S,5R,6R)-3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-tetrahydro-pyran-3-yl ester 
• 331233-74-0 3-(3-azido-4-benzyloxy-6-hydroxymethyl-5-methoxy-tetrahydro-pyran-2-yloxy)-4-benzyloxy-5-hydroxy-6-(3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 331233-72-8 5-acetoxy-3-(6-acetoxymethyl-3-azido-4-benzyloxy-5-methoxy-tetrahydro-pyran-2-yloxy)-4-benzyloxy-6-(3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 27851-26-9 (2S,3S,4S,5R,6R)-3,4,5,6-tetrakis(benzyloxy)tetrahydro-2H-pyran-2-carboxylic acid 
• 1187036-97-0 benzyl 2,3,4-tri-O-benzyl-6-O-(N-(2-ethyl-2,8-diazaspiro[4,5]decane-1,3-dione)aminocarbonyl)-β-D-glucopyranoside 

Relevant articles and documents

AMPHETAMINE PRODRUGS

The present invention relates to amphetamine prodrugs which provide colonic release of amphetamine.

COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyIoidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

Synthesis of glycosyl derivatives as dopamine prodrugs: Interaction with glucose carrier GLUT-1

Glucosyl dopamine (DA) derivatives may represent a new class of DA prodrugs that would interact with glucose transporter GLUT-1, present in the blood-brain barrier, and generate DA in the brain. Therefore, compounds bearing the sugar moiety linked to eith